Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.48 |
| ▸ | FABP1 | P07148 | 1/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10846536 | 0.77 | LTA4H (0.52) | MEN1KMT2APOLBLMNAGAA | |
| SCHEMBL6866111 | 0.77 | L3MBTL1 (0.85) | MEN1KMT2AL3MBTL1PKMPOLB | |
| SCHEMBL2402016 | 0.76 | KMT2A (0.65) | MEN1KMT2AL3MBTL1PKMPOLB | |
| SCHEMBL2400768 | 0.75 | KMT2A (0.63) | MEN1KMT2AL3MBTL1PKMPOLB | |
| SCHEMBL22305399 | 0.73 | KCNK3 (0.83) | MEN1KMT2AL3MBTL1PKMPOLB | |
| SCHEMBL11780085 | 0.73 | L3MBTL1 (0.67) | MEN1KMT2AL3MBTL1PKMPOLB | |
| SCHEMBL9393008 | 0.71 | RAB9A (0.55) | MEN1KMT2AL3MBTL1POLBLMNA | |
| SCHEMBL11037765 | 0.71 | CASR (0.55) | MEN1KMT2AL3MBTL1FNTAFNTB | |
| SCHEMBL14758994 | 0.70 | L3MBTL1 (1.00) | MEN1KMT2AL3MBTL1PKMPOLB | |
| SCHEMBL6265712 | 0.70 | L3MBTL1 (0.78) | MEN1KMT2AL3MBTL1PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386539-B1 | 4-Aminoproline derivatives useful as lysine mimetics | ZEALAND PHARMA AS (DK) | 2016-07-20 | — | — | EP | disclosed |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-08-29 | — | — | US | disclosed |
| US-8431540-B2 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2013-04-30 | — | — | US | disclosed |
| US-20120245106-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2012-09-27 | — | — | US | disclosed |
| EP-2386539-A2 | Modified lysine-mimetic compounds | Zealand Pharma A/S (DK) | 2011-11-16 | — | — | EP | disclosed |
| US-D647202-S1 | Bone marrow harvesting device | WARSAW ORTHOPEDIC, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8026272-B2 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2011-09-27 | — | — | US | disclosed |
| US-20100249206-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | Zealand Pharma A/S and Wyeth | 2010-09-30 | — | — | US | disclosed |
| US-7622496-B2 | antiarrhythmia agents; 1-(2-Amino-acetyl)-4-(benzoylamino)-pyrrolidine-2-carboxylic acid; desirable bioavailability properties | ZEALAND PHARMA A/S (DK) | 2009-11-24 | — | — | US | disclosed |
| EP-1966130-A2 | MODIFIED LYSINE-MIMETIC COMPOUNDS | Zealand Pharma A/S (DK) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007078990-A2 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2007-07-12 | — | — | WO | disclosed |
| US-20070149460-A1 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245106-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | MEN1 1114/4885KMT2A 89/4885L3MBTL1 112/4885 |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | MEN1 1114/4885KMT2A 89/4885L3MBTL1 112/4885 |
| US-20100249206-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | MEN1 1114/4885KMT2A 89/4885L3MBTL1 112/4885 |
| US-20070149460-A1 | Modified lysine-mimetic compounds | MYLK2, KCNN2, KCNN1 | MEN1 1114/4885KMT2A 89/4885L3MBTL1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.